171 related articles for article (PubMed ID: 22343093)
21. Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease.
Tomlinson SM; Watowich SJ
Biochemistry; 2008 Nov; 47(45):11763-70. PubMed ID: 18855422
[TBL] [Abstract][Full Text] [Related]
22. Intrinsic flexibility of West Nile virus protease in solution characterized using small-angle X-ray scattering.
Garces AP; Watowich SJ
Biochemistry; 2013 Oct; 52(39):6856-65. PubMed ID: 24015950
[TBL] [Abstract][Full Text] [Related]
23. Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9,10-dihydro-3H,4aH-1,3,9,10a-tetraazaphenanthren-4-one scaffold.
Samanta S; Cui T; Lam Y
ChemMedChem; 2012 Jul; 7(7):1210-6. PubMed ID: 22550001
[TBL] [Abstract][Full Text] [Related]
24. Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.
Martinez AA; Espinosa BA; Adamek RN; Thomas BA; Chau J; Gonzalez E; Keppetipola N; Salzameda NT
Eur J Med Chem; 2018 Sep; 157():1202-1213. PubMed ID: 30193218
[TBL] [Abstract][Full Text] [Related]
25. Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors.
Tomlinson SM; Watowich SJ
Antiviral Res; 2012 Feb; 93(2):245-252. PubMed ID: 22193283
[TBL] [Abstract][Full Text] [Related]
26. Context-Dependent Cleavage of the Capsid Protein by the West Nile Virus Protease Modulates the Efficiency of Virus Assembly.
VanBlargan LA; Davis KA; Dowd KA; Akey DL; Smith JL; Pierson TC
J Virol; 2015 Aug; 89(16):8632-42. PubMed ID: 26063422
[TBL] [Abstract][Full Text] [Related]
27. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease.
Hammamy MZ; Haase C; Hammami M; Hilgenfeld R; Steinmetzer T
ChemMedChem; 2013 Feb; 8(2):231-41. PubMed ID: 23307694
[TBL] [Abstract][Full Text] [Related]
28. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.
Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R
Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis and characterization of novel 1,2-benzisothiazol-3(2H)-one and 1,3,4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases.
Lai H; Dou D; Aravapalli S; Teramoto T; Lushington GH; Mwania TM; Alliston KR; Eichhorn DM; Padmanabhan R; Groutas WC
Bioorg Med Chem; 2013 Jan; 21(1):102-13. PubMed ID: 23211969
[TBL] [Abstract][Full Text] [Related]
30. A P2 and P3 substrate specificity comparison between the Murray Valley encephalitis and West Nile virus NS2B/NS3 protease using C-terminal agmatine dipeptides.
Ang MJ; Li Z; Lim HA; Ng FM; Then SW; Wee JL; Joy J; Hill J; Chia CS
Peptides; 2014 Feb; 52():49-52. PubMed ID: 24333681
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.
Erbel P; Schiering N; D'Arcy A; Renatus M; Kroemer M; Lim SP; Yin Z; Keller TH; Vasudevan SG; Hommel U
Nat Struct Mol Biol; 2006 Apr; 13(4):372-3. PubMed ID: 16532006
[TBL] [Abstract][Full Text] [Related]
32. NMR analysis of the dynamic exchange of the NS2B cofactor between open and closed conformations of the West Nile virus NS2B-NS3 protease.
Su XC; Ozawa K; Qi R; Vasudevan SG; Lim SP; Otting G
PLoS Negl Trop Dis; 2009 Dec; 3(12):e561. PubMed ID: 19997625
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in vitro evaluation of West Nile virus protease inhibitors based on the 2-{6-[2-(5-phenyl-4H-{1,2,4]triazol-3-ylsulfanyl)acetylamino]benzothiazol-2-ylsulfanyl}acetamide scaffold.
Samanta S; Lim TL; Lam Y
ChemMedChem; 2013 Jun; 8(6):994-1001. PubMed ID: 23619931
[TBL] [Abstract][Full Text] [Related]
34. Homology modeling and molecular dynamics study of West Nile virus NS3 protease: a molecular basis for the catalytic activity increased by the NS2B cofactor.
Zhou H; Singh NJ; Kim KS
Proteins; 2006 Nov; 65(3):692-701. PubMed ID: 16972281
[TBL] [Abstract][Full Text] [Related]
35. Selective inhibition of the West Nile virus methyltransferase by nucleoside analogs.
Chen H; Liu L; Jones SA; Banavali N; Kass J; Li Z; Zhang J; Kramer LD; Ghosh AK; Li H
Antiviral Res; 2013 Mar; 97(3):232-9. PubMed ID: 23267828
[TBL] [Abstract][Full Text] [Related]
36. A Molecular Determinant of West Nile Virus Secretion and Morphology as a Target for Viral Attenuation.
Basset J; Burlaud-Gaillard J; Feher M; Roingeard P; Rey FA; Pardigon N
J Virol; 2020 Jun; 94(12):. PubMed ID: 32269117
[TBL] [Abstract][Full Text] [Related]
37. Peptide-β-lactam Inhibitors of Dengue and West Nile Virus NS2B-NS3 Protease Display Two Distinct Binding Modes.
Dražić T; Kopf S; Corridan J; Leuthold MM; Bertoša B; Klein CD
J Med Chem; 2020 Jan; 63(1):140-156. PubMed ID: 31804823
[TBL] [Abstract][Full Text] [Related]
38. Phosphonate inhibitors of West Nile virus NS2B/NS3 protease.
Skoreński M; Milewska A; Pyrć K; Sieńczyk M; Oleksyszyn J
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):8-14. PubMed ID: 30362835
[TBL] [Abstract][Full Text] [Related]
39. Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase.
Shiryaev SA; Cheltsov AV; Gawlik K; Ratnikov BI; Strongin AY
Assay Drug Dev Technol; 2011 Feb; 9(1):69-78. PubMed ID: 21050032
[TBL] [Abstract][Full Text] [Related]
40. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease.
Nall TA; Chappell KJ; Stoermer MJ; Fang NX; Tyndall JD; Young PR; Fairlie DP
J Biol Chem; 2004 Nov; 279(47):48535-42. PubMed ID: 15322074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
